Anti inflammatory effects of statin in COPD

Introduction: Statins are now becoming recognized as powerful antiinflammatory agents that exert beneficial effects beyond low-density lipoprotein cholesterol reduction [1]. COPD patients receiving statins obtain a benefit from these therapeutic agents. Clearly, the best medical evidence for the ass...

Full description

Bibliographic Details
Main Authors: Nasef Abdelsalam Rezk, Ahmad Elewa
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Egyptian Journal of Chest Disease and Tuberculosis
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0422763813000083
id doaj-855c21db9d974c91bc5d5f94279ec6eb
record_format Article
spelling doaj-855c21db9d974c91bc5d5f94279ec6eb2020-11-25T00:15:12ZengWolters Kluwer Medknow PublicationsEgyptian Journal of Chest Disease and Tuberculosis0422-76382013-01-01621656910.1016/j.ejcdt.2013.01.006Anti inflammatory effects of statin in COPDNasef Abdelsalam Rezk0Ahmad Elewa1Chest Medicine, Mansoura University, EgyptClinical Pathology, Mansoura University, EgyptIntroduction: Statins are now becoming recognized as powerful antiinflammatory agents that exert beneficial effects beyond low-density lipoprotein cholesterol reduction [1]. COPD patients receiving statins obtain a benefit from these therapeutic agents. Clearly, the best medical evidence for the association of statins with improved outcomes for COPD patients [2]. We aimed in this study to assess anti inflammatory effects of statin in COPD patients. Patients and methods: We studied 28 patients with chronic obstructive lung disease. Fourteen patients (11 male and 3 female) receiving statin due to hyperlipidemia (9 patients received simvastatin and 5 patients atorvastatin), and other 14 patients (11 male and 3 female) not hyperlipidemic. All patients were subjected to Pulmonary function (spirometery) pre and at end of study. Sputum induction before and at end of 10 months from statin starting, and determination of leptin, total and differential cell count pre and at end of study. Results: After 10 months from statin intake we found significant decrease of TCC in statin groupand also high significant decrease of sputum leptin, neutrophils, and COPD exacerbation in the same group when compared to control group. And significant decrease of TCC in statin group pre and at end of study with high significant decreases of sputum leptin, neutrophils, and COPD exacerbation of statin group pre and 10 months of statin intake. Titropium bromide has positive significant effects on sputum leptin in statin group. Conclusion: We conclude that statin may lower the exacerbation in patients with chronic obstructive lung diseases and may lower the total cell count of inflammatory cells, sputum leptin and neutrophils.http://www.sciencedirect.com/science/article/pii/S0422763813000083StatinCOPD
collection DOAJ
language English
format Article
sources DOAJ
author Nasef Abdelsalam Rezk
Ahmad Elewa
spellingShingle Nasef Abdelsalam Rezk
Ahmad Elewa
Anti inflammatory effects of statin in COPD
Egyptian Journal of Chest Disease and Tuberculosis
Statin
COPD
author_facet Nasef Abdelsalam Rezk
Ahmad Elewa
author_sort Nasef Abdelsalam Rezk
title Anti inflammatory effects of statin in COPD
title_short Anti inflammatory effects of statin in COPD
title_full Anti inflammatory effects of statin in COPD
title_fullStr Anti inflammatory effects of statin in COPD
title_full_unstemmed Anti inflammatory effects of statin in COPD
title_sort anti inflammatory effects of statin in copd
publisher Wolters Kluwer Medknow Publications
series Egyptian Journal of Chest Disease and Tuberculosis
issn 0422-7638
publishDate 2013-01-01
description Introduction: Statins are now becoming recognized as powerful antiinflammatory agents that exert beneficial effects beyond low-density lipoprotein cholesterol reduction [1]. COPD patients receiving statins obtain a benefit from these therapeutic agents. Clearly, the best medical evidence for the association of statins with improved outcomes for COPD patients [2]. We aimed in this study to assess anti inflammatory effects of statin in COPD patients. Patients and methods: We studied 28 patients with chronic obstructive lung disease. Fourteen patients (11 male and 3 female) receiving statin due to hyperlipidemia (9 patients received simvastatin and 5 patients atorvastatin), and other 14 patients (11 male and 3 female) not hyperlipidemic. All patients were subjected to Pulmonary function (spirometery) pre and at end of study. Sputum induction before and at end of 10 months from statin starting, and determination of leptin, total and differential cell count pre and at end of study. Results: After 10 months from statin intake we found significant decrease of TCC in statin groupand also high significant decrease of sputum leptin, neutrophils, and COPD exacerbation in the same group when compared to control group. And significant decrease of TCC in statin group pre and at end of study with high significant decreases of sputum leptin, neutrophils, and COPD exacerbation of statin group pre and 10 months of statin intake. Titropium bromide has positive significant effects on sputum leptin in statin group. Conclusion: We conclude that statin may lower the exacerbation in patients with chronic obstructive lung diseases and may lower the total cell count of inflammatory cells, sputum leptin and neutrophils.
topic Statin
COPD
url http://www.sciencedirect.com/science/article/pii/S0422763813000083
work_keys_str_mv AT nasefabdelsalamrezk antiinflammatoryeffectsofstatinincopd
AT ahmadelewa antiinflammatoryeffectsofstatinincopd
_version_ 1725388192585089024